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SUMMARY 
The effects on 24-h survival and neurologic function were compared 
following continued postresuscitation circulatory support with epinephrine or 
dopamine. Cardiopulmonary arrest was induced by ventricular fibrillation. 
After 10 min, resuscitation efforts were initiated including i.v. infusion of 
either epinephrine (6 ccglkg per min, 11 dogs) or dopamine (10 rg/kg per min, 14 
dogs) for continued circulatory support. There was no difference detected in 
duration of circulatory support, although dogs receiving epinephrine required 
more lidocaine (3.3 f 0.4 vs. 1.8 f 0.3 mg/kg, P = 0.0051. Likewise, there was 
no statistically significant difference detected in MAP or HR between groups 
at any time tested. However, dogs receiving epinephrine had significantly 
worse neurologic function at 6 and 12 h postarrest. Mean survival time (20.3 + 
1.2 vs. 15.3 f 1.9 h, P = 0.0281 and overall survival Cp = 0.027, survival curve 
analysis) were significantly longer for dogs receiving dopamine. Plasma glucose 
in the first 6 h postarrest was significantly higher in dogs receiving epinephrine 
(P = 0.0061. These results suggest that the use of epinephrine for continued 
vasopressor support in cardiopulmonary resuscitation may contribute to 
decreased survival and poorer neurologic function in this controlled experimen- 
tal setting. It is reasonable to propose that similar responses to these 
commonly used circulatory support agents occur clinically. Therefore, 
continued vasopressor support with dopamine rather than epinephrine may be 
justified in the setting of cardiac resuscitation. 
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INTRODUCTION 
The most recent review panel dealing with the use of catecholamines in 
cardiopulmonary resuscitation (CPR) [l] stressed the importance of exogenous 
catecholamines in the restoration of circulation after cardiac arrest. The use of 
unopposed /3-adrenergic agonists was discouraged because of excessive 
myocardial chronotropic and inotropic effects, accompanied by potentially 
hazardous increases in myocardial oxygen consumption and reduced coronary 
blood flow [1,2]. Epinephrine, an alpha- and beta-adrenergic receptor agonist, 
was specifically recommended as a vasopressor during acute resuscitation from 
cardiac arrest [3]. The American Heart Association guidelines for circulatory 
support following the restoration of circulation made ‘no blanket 
recommendation for specific drugs’ and suggested selection of drugs based on 
‘the specific pharmacologic action that will allow the needed physiologic 
manipulation’ [3]. Therefore this study was designed to provide experimental 
information which may be useful in selection of the most suitable drugs for 
circulatory support. 
Resuscitation from cardiac arrest has two major components: (1) restoration 
of ventilation and adequate perfusion, especially to the myocardium and CNS 
and (2) maintenance of: (a) ventilation for adequate gas exchange, and (b) cardiac 
output and vascular resistance for adequate tissue perfusion. Unlike the 
substantial body of literature on the efficacy of catecholamines to restore 
spontaneous circulation [3-81, there is a paucity of information on desirable 
features for circulatory support following return of circulation. This study was 
designed to determine, in a controlled experimental setting, the neurologic 
morbidity and mortality associated with similar continued circulatory support 
with epinephrine or dopamine. 
MATERIALS AND METHODS 
We used a reproducible and consistent model [9 - 131 to address the question: 
do epinephrine and dopamine, administered for continued circulatory support 
after resuscitation from ventricular fibrillation, have differential effects on 
neurologic function and 24-h survival? Twenty-five adult male mongrel dogs 
weighing between 15.0 and 24.9 kg were randomly assigned to one of two treat- 
ment conditions. Eleven dogs received an infusion of 6 pg/kg per min 
epinephrine while 14 dogs received 10 pg/kg per min dopamine for circulatory 
support following CPR. Food but not water was withdrawn from all dogs 24 h 
prior to intramuscular premeditation with 1.5 mg/kg morphine sulfate. After 30 
min, anesthesia was induced with 5% halothane via mask and demand 
ventilation (Foregger, Compact-75, Puritan Bennett). Once anesthetized, the 
dogs were intubated and ventilated with l-2% halothane via controlled 
ventilation (Anesthesia Ventilator, Puritan Bennett) to maintain analgesia and 
suppression of cornea1 reflexes. An infrared analyzer (Beckman LB-21 was used 
to monitor expired carbon dioxide gas tension between 3 and 5%. Ventilation 
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and bicarbonate administration were manipulated to maintain blood pH 
between 7.38 and 7.41, as determined by frequent pre- and post-resuscitation 
arterial blood sampling (Instrumentation Laboratories 1131. Plasma glucose 
was determined spectrophotometrically (SERALYZER Reflectance 
Photometer). An esophageal temperature probe was inserted to the level of the 
heart, and body temperature was monitored and maintained at 39.0 -+ l.O°C 
with a heating pad and proportional controller prior to ventricular fibrillation. 
Two venous catheters were inserted, one passed through the left external 
jugular vein to the right atrium for central administration of drugs and fluids, 
and one in a branch of the femoral vein for epinephrine or dopamine 
administration. Pulsatile and mean arterial blood pressure were measured 
(Stathum P23XL transducer) through a catheter placed in a branch of the 
femoral artery. Subcutaneous electrodes were placed to monitor lead II 
electrocardiogram (ECG). 
The left chest was opened at the fifth intercostal space, and the pericardium 
opened to facilitate direct cardiac compression. All catheters and electrical 
leads were passed subcutaneously to exit the skin in the dorsal midscapular 
region for later attachment to the dog jacket and hydraulic/electric swivel. The 
ECG, arterial pressure, heart rate, and expiratory carbon dioxide were 
continuously recorded on a six-channel oscillograph (Gould-Brush 200). Each 
dog received 500 ml of isotonic saline (0.9% NaCll i.v. to assure adequate hydra- 
tion prior to arrest. 
Cardiac arrest 
When the preparation was complete, the administration of halothane was 
stopped and ventilation continued (Harvard 6071 with room air to reduce and 
standardize the level of anesthesia at which ventricular fibrillation was 
induced. When cornea1 reflexes had returned (Stage III, plane 1 level of surgical 
anesthesia), an arterial blood sample was drawn for baseline determinations of 
arterial glucose concentration and pH, ventilation was stopped, and the heart 
was fibrillated by delivering a 60 Hz, 2 ms square wave stimulus to the left 
ventricular epicardium. Circulatory arrest was confirmed by evaluation of the 
ECG tracing, arterial pressure, and by direct observation. 
Resuscitation 
After 10 min of ventricular fibrillation, ventilation was restored and direct 
cardiac massage maintained mean arterial blood pressure above 75 mmHg. 
Circulatory support was initiated by a central bolus i.v. injection of 40 rg/kg 
epinephrine in all dogs and continued vasopressor support with an infusion of 
either [l] 6 rg/kg per min epinephrine or [2] 10 pg/kg per min dopamine. This 
was followed in rapid succession by administration of: (11 lidocaine (1 mglkg), (2) 
sodium bicarbonate (4 meq/kg), and (31 calcium chloride (25 mg/kg). 
Defibrillation was attempted by delivering a charge of 40-80 J (Lifepak3, 
Physio-Control), with 31 cm2 paddles placed on the right and left ventricular 
surfaces. 
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The continuous epinephrine or dopamine infusion was adjusted to maintain 
mean arterial pressurebetween 85 and 120 mmHg, and the dogs were weaned 
from this support as soon as possible, or no later than 6 h postarrest. The chest 
was closed and the dogs were ventilated for up to 6 h or until spontaneous 
ventilation ensued, and were extubated upon the return of the gag reflex. 
Spectinomycin (10 mg/kg i.m.l was administered and morphine sulfate 
provided for analgesia if attention to wound sites or aggressive behavior 
suggested the presence of pain. The dogs were placed in a tethered dog jacket 
and swivel (Alice King Chatham Medical Arts) which permits three electrical 
and three hydraulic connections to be maintained while allowing the dog free 
movement about the cage. Dogs surviving to 24 h postarrest were euthanized 
with 120 mg/kg sodium pentobarbital i.v. following final blood sampling. Post- 
mortem examinations of the heart, lungs, and wound sites were conducted to 
identify iatrogeny. This experimental procedure conformed to guidelines 
established by the American Physiological Society and the ‘Guide for the Care 
and Use of Laboratory Animals’ (NIH Publication No. 85-23, 19851 and was 
TABLE I 
NEUROLOGIC DEFICIT SCORING PARAMETERS 
Neurologic deficit score (0 = no deficit; 100 = maximum deficit or death) consisting of five 
categories of function and increases with severity of damage. Dogs that die are included in the 
calculation of neurologic deficit score because their patterns of death were indicative of a primary 
cerebral event. 
Consciousness l&ore range: O-18/ 
Normal (0) 
Conscious continually (3) 
Conscious intermittently 63) 
Stuporous (12) 
Light coma (15) 
Deep coma (18) 
Spinal nerves (Score range: O-20) 
(Normal = 0, Spastic = 2, Flaccid = 4) 
Limb tone: front 
Limb tone: hind 
(Strong = 0, Weak = 2, Absent, Hyper = 4) 
Pain reflex: front 
Pain reflex: hind 
Knee jerk reflex 
Respiration IScore rdnge: O-181 Motorfunction /Score tinge: O-28) 
Normal (0) Normal (0) 
Extubatedlabnormal(6) Minimal ataxia (2) 
Intubated/spontaneous (12) Ataxia (4) 
On ventilator (18) Stands spontaneously (6) 
Cranial nerves (Score mnge: O-161 Stands if posed (8) 
(Strong = 0, Weak = 1, Absent = 2) Sits spontaneously (10) 
Corneai reflex Sits if posed (12) 
Pupiilary light reflex Spontaneous dorsal recumbancy (14) 
Facial sensation Posed dorsal recumbancy (16) 
Gag reflex Spontaneous purposeful (18) 
Jaw reflex Provoked purposeful (20) 
Pinna reflex Reflex, spastic, or convulsive movement 
Olfactory reflex only (24) 
Swallowing reflex No movement (28) 
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approved by The University of Michigan Unit for Laboratory Animal 
Medicine’s Vertebrate Animal Use Committee (approval No. DO01068Dl. 
Evaluation of neurologic deficit 
A well-standardized neurologic score (Table 11 was assigned at 1,2,6,12, and 
24 h postarrest by an experienced investigator unaware of the hypothesis 
being tested. The score ranges from 0 to 100, with 0 indicating normal 
neurologic function while a score of 100 indicates maximal neurologic deficit. A 
written description for each neurologic level being assessed was consulted to 
ensure minimal interobserver variability [13]. 
Effect of epinephrine and dopamine on plasma glucose in intact dogs 
Four intact dogs were instrumented with arterial and venous cannulae 
under halothane anesthesia. Following recovery, 1.36 rg/kg per min 
epinephrine or 24.4 pg/kg per min dopamine were infused intravenously. 
Comparable levels of mean arterial pressure elevation were achieved by these 
doses. Arterial plasma glucose was determined before, every 15 min during, 
and for 1 h following the 75-min vasopressor infusion. 
Statis tical analysis 
Based on previous experience with neurologic deficit scoring in this 
experimental paradigm, ten animals per group will provide a power of at least 
90% when tested at a 5% level of significance. Significant differences in 
survival rates can be detected when the rates differ by 30% with 15 animals 
per group. Multiple linear regression analysis was used to determine if the pre- 
TABLE II 
PRE-ARREST VARIABLES 
Average pre-arrest physiologic variables (mean f 1 S.E.M.). P values determined by Student’s t- 
analysis. Sample sixes for epinephrine and dopamine groups are 11 and 14 respectively @a = 7). 




Operative tie (min) 
Body weight (kg) 
MAP (mmHg) 
Heart rate (beats/mini 
Arterial pH 
End expiratory CO, (96) 
Plasma glucose (mM) 
Core temperature (“Cl 
11 
43.3 f 8.6 
19.7 f 1.2 
129 + 6 
114 f 13 
7.39 f 0.02 
3.6 f 0.2 
7.7 f 0.3 




33.4 f 2.9 
18.6 f 0.3 
126 f 6 
102 f 6 
7.41 f 0.02 
3.8 f 1.2 
6.9 f 0.3 












arrest variables (Table II) were associated with neurologic outcome and 
survival. The pre-arrest and resuscitation variables (resuscitation time, 
number of countershocks, ventilation time, extubation time, dose of 
resuscitation drugs, and epinephrine or dopamine infusion time), and plasma 
glucose levels were compared using the Student’s t-test. Neurologic deficit 
scores were compared parametrically (Student’s tl and non-parametrically 
(Mann-Whitney U), and P values for both tests are reported. Plasma glucose 
levels in the first 6 h postarrest were compared by profile analysis. Fisher’s 
exact analysis and Breslow survival curve analysis [14] provided significance 
values for survival data. Statistical analyses were performed using the Michi- 
gan Interactive Data Analysis System (MIDAS) and BMDP Statistical Software 
on an IBM 3090400 computer. The mean f one standard error of the mean 
(S.E.M.) are reported in all text, tables, and figs. Exact P values are reported 
and P values of less than 0.05 are considered statistically significant. 
RESULTS 
The average values for pre-arrest variables are provided in Table II. Using 
multiple linear regression analytic techniques, there was no evidence of an 
association of the pre-arrest variables (operative time, body wt., mean arterial 
pressure, heart rate, arterial pH, plasma glucose, and body temperature) with 
survival time. Nor was there any significant or consistent relationship between 




Average resuscitation variables (mean f 1 S.E.M.). P values for resuscitation time, number of 
countershocks, extubation time, and epinephrineldopamine infusion time determined by Student’s 
t-analysis. Sample sixes for epinephrine and dopamine groups are 11 and 14 respectively. Gunple 
size = 10. Resuscitation time is the time from the start of the resuscitation until the dog’s MAP > 






Resuscitation time (min) 
Countershocks 
Extubation time (min) 
Epi. or DA infusion time (min) 
Epinephrine inj. dose fpg/kg) 
Lidocaine dose (mglkg) 
Sodium bicarbonate (meqlkg) 
Calcium chloride dose Gng/kgI 
11 
3.6 f 0.6 
2.0 f 0.4 
288 f 38 
103 * 32 
52.8 f 6.2 
3.3 f 0.4 
6.4 f 0.4 
27.3 f 2.3 
14 
2.6 f 0.3 
1.6 f 0.2 
308 * 19 
77 f 27 
44.3 f 2.3 
1.8 f 0.3 
4.7 f 0.4 
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Fig. 1. Plasma glucose concentration in mM pre- and to 6 h postarrest. Higher plasma glucose profile 
for epinephrine-receiving group during 6 h postarrest (P = 0.0065). 
All 25 dogs were successfully resuscitated as indicated by the return of 
spontaneous ventilation and MAP greater than 75 mmHg. Table III presents a 
comparison of resuscitation procedure variables. There was no statistical 
difference in the duration of vasopressor support between groups. Dogs 
receiving epinephrine required more lidocaine to treat dysrhythmias (3.3 + 0.4 
vs. 1.8 f 0.3 mglkg, P = 0.005). Although pre-arrest mean plasma glucose 
concentrations were not different between the groups (Fig. 11, dogs receiving 
the epinephrine infusion were more hyperglycemic than dopamine-receiving 
dogs during the first 6 h postarrest (P = 0.0061. There was no difference in 
plasma glucose at 12 h postarrest (epinephrine infused: 4.7 f 0.7 mM dopamine 
infused: 4.5 f 0.2 mM1. In a separate series of intact dogs, epinephrine 
significantly (P = 0.05) elevated plasma glucose in contrast to dopamine (Fig. 
21, despite the use of a lower dose of epinephrine and a higher dose of dopamine 
than administered in resuscitated dogs. In this series, plasma glucose levels 
were found to be significantly higher than control levels at 60 and 75 min in four 
dogs infused with epinephrine by Student’s paired t-analysis. An equipotent 
vasopressor infusion of dopamine did not significantly change plasma glucose in 
four other animals. 
Neurologic function was evaluated at 1,2,6,12, and 24 h postarrest using the 
loo-point scoring system outlined in Table I. Mean neurologic deficit scores at 
each time is illustrated in Fig. 3. Dogs receiving epinephrine for circulatory 
support had consistently higher neurologic deficit scores (more damage). This 
difference was statistically significant by Student’s t and Mann-Whitney U 




30 60 90 120 150 
TIME (minutes) 
Fig. 2. Percent of control plasma glucose before, during, and after 75 min of epinephrine b = 4) or 
dopamine (n = 4) infusion in intact dogs. Epinephrine stimulated significantly greater elevations in 
plasma glucose at 60 and 76 min of infusion compared to control levels, and compared to dopamine 
infusion. ??P < 0.05 by Student’s t-analysis. 
1 2 6 12 
HOURS POST-ARREST 
T * 
Fig. 3. Postresuscitation neurologic deficit (0 = no deficit; 100 = maximum deficit or death). Values 
are the total neurologic score for all dogs (mean f 18.E.M.). Dogs dying from primary neurologic 
dysfunction receive neurologic score of 100. Dogs receiving epinephrine b = 11 except at 12 h n = 
9) are indicated by the white bars; those receiving dopamine b = 141, cross-hatched bars. Animals 
receiving epinephrine showed consistently worse neurologic function at all scoring times. ??P < 0.06 
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Fig. 4. Twenty-four hour survival curves following 10 min of cardiac arrest and resuscitation. Profile 
analysis of the survival curve by the Breslow test indicates significantly greater survival in animals 
receiving dopamine (P = 0.027). 
0.013 and P = 0.048, respectively). Only eight animals survived to 24 h, includ- 
ing two that received epinephrine and six that received dopamine. Because of 
this, available statistical power was insufficient to detect statistically 
significant neurologic differences at 24 h using Student’s t and Mann-Whitney 
U analyses. The mean survival time for the epinephrine group was 15.3 f 1.9 h 
which was significantly P = 0.028) shorter than the 20.3 f 1.2 h survival for 
the dopamine-treated group. Similar differences were revealed by Breslow 
survival curve analysis (Fig. 4, P = 0.027). 
80- 
60- 
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Fig. 6. Mean arterial pressure pre-arrest and during the recovery period. There is no difference in 
MAP between the groups at any time. Pressor support was provided during the Fist 6 h postarrest 
as necessary. Sample sizes are indicated next to the data point. 
The average mean arterial pressure pre-arrest (control), and at 6,7,12, and 
18 h postarrest (Fig. 51 were not different between the groups. These curves 
indicate that each group maintained a similar MAP, independent of previous 
treatment, following weaning from vasopressive agents. When MAP exceeded 
75 mmHg without mechanical support, end expiratory CO, did not differ 
between the groups (5.9 & 0.6%. 5.7 f 0.3%; epinephrine and dopamine 
treated, respectively). However, end expiratory CO, upon return of 
spontaneous ventilation was significantly lower, P = 0.01, in the group of dogs 
receiving dopamine (3.0 -+ 0.2%) compared to those receiving epinephrine (4.0 
f 0.3%). 
DISCUSSION 
Dopamine and epinephrine are two frequently administered vasopressor 
agents in the treatment of postresuscitation hypotension associated with 
cardiac arrest [1,2,6,7]. Data reported above compare possible secondary effects 
of epinephrine and dopamine when used during the maintanence phase of 
resuscitation for continued circulatory support. Although other studies have 
examined the therapeutic efficacy of these drugs in the setting of cardiac arrest 
and resuscitation [6,7], only one study compared the effects on postarrest 
neurologic outcome of circulatory support agents, and in that case epinephrine 
and phenylephrine were compared [8]. Epinephrine and phenylephrine had 
similar effect on cardiovascular and neurologic outcome in this canine model 
of 12 min cardiac arrest. 
The current study assessed the effects, in a controlled experimental 
protocol, of dopamine and epinephrine infusions, on neurologic function and 
mortality in cardiac resuscitation. Dogs receiving continued circulatory 
support with epinephrine had consistently greater neurologic deficits (poorer 
neurologic function) and increased 24 h mortality than animals receiving 
dopamine. Maintenance of a higher perfusion pressure cannot account for the 
improved neurologic function since both agents were administered to maintain 
mean arterial pressure above 85 mmHg. In addition, the mean infusion times 
for epinephrine and dopamine groups (103 f 32 and 77 k 27 min, respectively) 
were not statistically different, however the length of infusion varied 
substantially between animals, within each group. Properties other than direct 
vasopressor functions of these compounds need to be considered in order to 
account for the improved neurologic function associated with dopamine 
infusion. 
The cerebral vasculature has rich autonomic innervation, and cerebral blood 
flow (CBF) may be directly altered by either parasympathetic or sympathetic 
activation. Epinephrine has no significant vasoconstrictor action on cerebral 
arterioles at the doses used in this study; its only effects on CBF are due to 
changes in systemic blood pressure [15]. In the dog, dopamine has a dose-depen- 
dent effect on CBF. CBF increases 20 - 40% of control levels in response to 2- 
6 pg/kg per min dopamine, but higher and lower doses of dopamine did not alter 
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CBF [16]. Nakagawa reports that when CBF is reduced 50% by middle cerebral 
artery occlusion in dogs, 5, 10, and 20 pg/kg per min dopamine augments CBF 
by 12-14%, concurrent with slight changes in MAP [17]. Ischemic, 
hypotensive, and hypertensive events are reported to alter blood-brain barrier 
function and hence could increase cerebral vascular reactivity to circulating 
alpha receptor agonists. Epinephrine might therefore have a greater 
vasoconstrictor effect on the CNS than dopamine once the blood-brain barrier 
is disrupted. This possible reduction in CBF may account for epinephrine’s dele- 
terious effects on neurologic function. Alternatively, it is possible that the dif- 
ferential effects of dopamine and epinephrine on neurologic function may be 
related to indirect effects on CBF. Since the duration of cerebral ischemia, pre- 
and postischemic metabolic parameters (pH, Pco,, etc.), and systemic 
hemodynamic parameters were generally not different between the dopamine- 
and epinephrine-receiving groups, the differences in neurologic deficit would 
probably not reflect different indirect effects of these drugs on CBF. An 
exception is the statistical difference in postarrest CO, between groups. The 
high CO, in the epinephrine-treated group would have produced a high CBF 
and potentially, therefore, an improved outcome. The reverse was observed. In 
any case, CBF was not monitored in this initial study. 
Although epinephrine and dopamine have both alpha- and beta-adrenergic 
receptor stimulating ability depending on dose, their other systemic metabolic 
properties are dissimilar. An alternative hypothesis for the adverse effect of 
epinephrine is related to its effect on glucose metabolism. Epinephrine quickly 
and dramatically elevates blood gluaose by beta-adrenergic receptor 
interaction in the liver, skeletal muscle, and adipose tissue. In animals not 
receiving exogenous glucose, a peak in plasma glucose is seen within the first 
hour postarrest, due presumably to the stress of the cardiac arrest and the 
bolus injections of epinephrine during the resuscitation effort. As demon- 
strated in Fig. 1, plasma glucose concentrations were significantly higher in the 
group receiving an infusion of epinephrine during the first 6 h postarrest. The 
elongation of the glucose peak is probably due to the metabolic actions of the 
infused epinephrine: stimulation of glycogenolysis and inhibition of insulin 
release, keeping glucose levels elevated in the blood. In the intact dogs (Fig. 2) 
the gradual and progressive increases in plasma glucose following epinephrine 
administration (at a dose that is 20% of the initial dose administered during 
cardiac resuscitation1 was not paralleled in the dogs given an infusion of dopa- 
mine by similar changes in blood glucose. In this case the dopamine was infused 
at a rate double the initial resuscitation dose. The association between 
hyperglycemia and augmented ischemic tissue damage has been well-docu- 
mented [9,11,18-2231 and it is likely that some of epinephrine’s adverse effects 
in this setting are mediated through tissue glucose metabolism. 
An additional undesirable effect of epinephrine is increased myocardial 
irritability. Dogs in this study who received epinephrine infusion required 
almost three times more lidocaine to treat dysrhythmias than dopamine-receiv- 
ing animals (Table III). These same animals also required more sodium 
2a4 
bicarbonate to correct metabolic acidosis, possibly caused by glycogenolysis- 
induced byperlacticacidemia. 
Methodological considerations 
This model has been developed to mimic postischemic encephalopathy 
common to humans who have been successfully resuscitated from cardiac 
arrest. Therefore an objective of this model is a high rate of successful return of 
spontaneous circulation. To this end, we have modified standard, human 
resuscitation protocols to optimize successful resuscitation of the dog after 
prolonged, normothermic ventricular fibrillation. These modifications include: 
(1) open chest ventricular fibrillation and defibrillation to allow lower energy 
for countershock, (21 direct cardiac compressions, which devleops MAP > 100 
mmHg within 1 min, for improved tissue blood flow and circulatory distribution 
of resuscitation drugs, (31 central administration of an initial dose of all 
resuscitation drugs in rapid succession (within 1.5 mini at the start of cardiac 
compressions (before the first countershock), (41 the use of sodium bicarbonate 
to rapidly correct ischemia-induced systemic acidosis which enhances 
myocardial contractility and reduces systemic vasodilation, and (51 the 
administration of 25 mg/kg calcium chloride which has not proven to be 
detrimental in our canine resuscitation efforts; on the contrary, this dose can 
rapidly correct electromechanical dissocation (which we infrequently see). 
Therefore, although this experimental resuscitation procedure does not exactly 
simulate ACLS protocols for humans, it has proven in our hand to be a useful 
model to study the mechanisms of ischemic neurologic damage. The use of 24-h 
survival and neurologic deficit scoring limits the interpretation of these data in 
that long-term recovery may not be a reflection of this short-term outcome. 
However, the effects of sepsis, nutrition, quality and quantity of nursing care, 
and humane concerns detracts from the usefulness of a long-term recovery 
study for the questions addressed in this study. 
CONCLUSIONS 
Because CNS function is already compromised subsequent to cardiac arrest, 
cardiac resuscitation therapy should attempt to restore, or at least protect, 
neurologic function concurrent with restoration of circulation. These data 
indicate that dopamine may be a safer and more effective agent for the 
maintenance of circulatory support following cardiac arrest. 
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